Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women...

Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer ( Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA )

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by...

Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC ( Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA )

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in...

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Oral paclitaxel with encequidar in metastatic breast cancer

Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras

Oral paclitaxel with encequidar in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

Predicting disease recurrence in patients with early triple-negative breast...

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...

Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )

The emerging role of immunotherapy for the treatment of early and advanced...

Dr Rita Nanda - UChicago Medicine, Chicago, USA

The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

More from ecancer